Tag archive for immunotherapies

- Jul 10 2017
- PDS-Biotech
PDS announces clinical collaboration with Merck
- Standard
- clinical trial, immuno-oncology, immunotherapies, Keytruda, Merck, PDS Biotechnology, PDS0101, versamune
PDS Biotechnology Corporation (“PDS”) has entered a clinical trial collaboration agreement with a subsidiary of Merck to evaluate the combination of Versamune® with Merck’s anti-PD-1 therapy, KEYTRUDA®.
Read more
- Jun 07 2016
- PDS-Biotech
PDS Biotechnology Release: CEO Frank Bedu-Addo Presenting at BIO 2016
- Standard
- CD8 + T-cell induction results, clinical stage, Frank Bedu-Addo, immuno-oncology, immunotherapies, PDS Biotechnology
North Brunswick, NJ: PDS Biotechnology, a private clinical stage immuno-oncology company developing novel immunotherapies, announces that CEO Frank Bedu-Addo will make a presentation at BIO 2016, being held at the Moscone Center, 747 Howard Street, San Francisco, California from June […]
Read more

©2017 PDS Biotechnology Corporation. All rights reserved.

Scroll